PAVM
PAVmed Inc.
There isn't enough reported data to score PAVM yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
PAVM Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Under pressure | |
| Unavailable |
PAVM's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
PAVM PE Valuation
PAVM has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
PAVM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect PAVM's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
PAVM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$129.90 | +$189.83 |
| Q2 2024 | -$245.10 | +$133.13 |
| Q1 2024 | -$272.40 | +$173.33 |
| Q4 2023 | -$274.80 | +$179.93 |
| Q3 2023 | -$319.73 | +$134.77 |
| Q2 2023 | -$378.23 | +$13.27 |
| Q1 2023 | -$445.73 | -$121.73 |
| Q4 2022 | -$454.73 | -$162.23 |
UNH has the stronger earnings trend. Trailing diluted EPS is down 107% for PAVM versus UNH down 8.5%.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
PAVM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $33K | +450% |
| Q1 2026 | $22K | +175% |
| Q3 2025 | $5K | -100% |
| Q2 2025 | $6K | -99% |
| Q1 2025 | $8K | -99% |
| Q3 2024 | $1M | +26% |
| Q2 2024 | $1M | +502% |
| Q1 2024 | $1M | +124% |
PAVM's revenue is recovering but still below its 2023 peak: $33,000 last quarter, up 450% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -21279% | +57305 points |
| Q1 2026 | -36523% | +31552 points |
| Q4 2025 | -13083% | N/A |
| Q3 2025 | -96880% | -95722 points |
| Q2 2025 | -78583% | -77215 points |
| Q1 2025 | -68075% | -66671 points |
| Q3 2024 | -1158% | +805 points |
| Q2 2024 | -1368% | +8562 points |
PAVM's operating margin was −21279% last quarter, up 57305 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over PAVM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over PAVM on profitability, with a higher operating margin.
PAVM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.7M | -$1.5M |
| Q1 2026 | -$2.6M | -$1.1M |
| Q4 2025 | -$1.6M | -1839% |
| Q3 2025 | -$899K | +$8M |
| Q2 2025 | -$1.2M | +$10.5M |
| Q1 2025 | -$1.6M | +$11.6M |
| Q4 2024 | $90K | +$12.1M |
| Q3 2024 | -$8.9M | +$2.2M |
PAVM has burned cash in almost every quarter: −$8M over the past year, against −$12M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over PAVM on cash generation, producing positive trailing cash flow while its opponent burns cash.
PAVM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +297% | +4.7M shares |
| 1 year | +940% | +5.7M shares |
| 3 years | +3067% | +6.1M shares |
| 5 years | +5731% | +6.2M shares |
| Available history | +8992% | +6.2M shares |
PAVM has 6M diluted shares, up 940% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over PAVM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
PAVM Net Leverage
PAVM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
PAVM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 21.8 | Oversold |
| Stochastic | 2.5 | Oversold |
PAVM's weekly RSI is 22 (oversold) and its Stochastic is 3 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
PAVM PE vs Healthcare Sector
PAVM has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
PAVM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.37 | 43% below |
| 20 week MA | $3.97 | 66% below |
| 50 week MA | $6.56 | 80% below |
| 100 week MA | $12.0 | 89% below |
| 200 week MA | $59.1 | 98% below |
PAVM is in a downtrend: it's below all five of its weekly moving averages, and 98% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over PAVM on trend strength, trading above more of its moving averages.
PAVM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $517.5 | $877.5 | +70% |
| 2021 | $877.5 | $1,242.0 | +42% |
| 2022 | $1,242.0 | $227.3 | -82% |
| 2023 | $227.3 | $123.6 | -46% |
| 2024 | $123.6 | $19.4 | -84% |
| 2025 | $19.4 | $8.68 | -55% |
| 2026 YTD | $8.68 | $1.34 | -85% |
PAVM has finished four years in a row lower, and it's down 85% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over PAVM on returns for 2026, with the stronger performance.